期刊
BRITISH JOURNAL OF OPHTHALMOLOGY
卷 98, 期 -, 页码 7-10出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/bjophthalmol-2013-303844
关键词
-
资金
- Alcon
- Allergan
- Genentech
- Novartis
- Ophthotech
- Regeneron
- Replenish
Anti-vascular endothelial growth factor (VEGF) therapy has revolutionised the treatment of retinal disease, and appears to be very safe. Nevertheless, there are several lines of evidence that imply that small doses of these agents could potentially have a systemic effect. The clinical significance of these systemic effects remains unclear, but further study is indicated.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据